Dr. Pawel Kalinski Dr. Pawel Kalinski

Pawel Kalinski

MD, PhD

Specializing In:

Biology of dendritic cells (DC) and DC vaccines Biology of T cells and T cell targeting therapies of cancer Biology of natural killer (NK) cells Biology of human myeloid-derived suppressor cells (MDSC) Regulation of chemokine production in tumor microenvironment (TME) TME and tumor-associated immune suppression In vitro modeling of human immune system Design and implementation of early phase clinical trials

Special Interests:

Development and clinical evaluation of new cancer involving the modulation of patients' immune system Role of the immune system in the effectiveness of chemo- and radiotherapy Promoting interactions between clinical and laboratory researchers Development and clinical evaluation of therapeutic vaccines involving different subsets of “polarized” DCs (colorectal cancer, ovarian cancer, prostate cancer, melanoma, hematologic malignancies) Development and clinical evaluation of adoptive T cell therapies (ACT) using ex vivo-induced polyclonal CTLs (ovarian- & colorectal cancers and melanoma) Development and clinical evaluation of combinatorial approaches to enhance the effectiveness of vaccines, ACT an checkpoint blockers, but reprogramming tumor microenvironments for enhanced CTL infiltration and modulating intratumoral expression of PD-L1, Development of combinatorial adjuvants to modulate DC functions in situ Counteracting cancer-related immunosuppressive mechanisms and their use in transplantation and autoimmunity Role of the immune system in the effectiveness of oncolytic virotherapies Role of the immune system in the effectiveness of chemotherapy and radiotherapy of cancer Interplay between stress and cancer immunity

About Me

Biography:

The overall goal of my research is to advance the integration of immunotherapy within comprehensive cancer care, as a complementary modality to surgery, chemo and radiotherapy. My group develops new methods of using ex vivo-educated dendritic cells, DC-activated T cells, combinatorial adjuvants and checkpoint blockers, to promote selectively accumulation of type-1 immune cells (CTLs, Th1 and NK cells) in tumor lesions, without amplifying pre-existing Treg- and MDSC responses, in order to enhance local immune surveillance and enhance overall therapeutic outcomes. Our current projects include:

  • Development and clinical evaluation of therapeutic vaccines involving different subsets of “polarized” DCs (colorectal cancer, ovarian cancer, prostate cancer, melanoma, hematologic malignancies)
  • Development and clinical evaluation of adoptive T cell therapies (ACT) using ex vivo-induced polyclonal CTLs (ovarian- & colorectal cancers and melanoma)
  • Development and clinical evaluation of combinatorial approaches to enhance the effectiveness of vaccines, ACT and checkpoint blockers, but reprogramming tumor microenvironments for enhanced CTL infiltration and modulating intratumoral expression of PD-L1, PD-L2 and other checkpoints (colorectal cancer, ovarian cancer, prostate cancer, melanoma, bladder cancer, HPV-associated cancers)
  • Development of combinatorial adjuvants to modulate DC functions in situ
  • Counteracting cancer-related immunosuppressive mechanisms and their use in transplantation and autoimmunity
  • Role of the immune system in the effectiveness of oncolytic virotherapies
  • Role of the immune system in the effectiveness of chemotherapy and radiotherapy of cancer
  • Interplay between psychologic stress and cancer immunity These interdisciplinary projects involving multiple clinical and laboratory teams, have been advanced as parts of the as multiple NIH-, DOD-, pharma and biotech-funded grants and program projects (single- and multi-institution P01s and P50/SPOREs; where I have been serving as the overall PI, overall co-PI or a Project Leader) and focusing on the therapy of melanoma, colon cancer, prostate cancer, ovarian cancer, and hematologic malignancies. Our current work includes phase I/II and phase II clinical testing of the resulting paradigms and methods in cancer patients, and development of similar treatments for patients with premalignant lesions and chronic infections resistant to standard forms of treatment.

Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Vice Chair for Translational Research, Department of Medicine
  • Director of Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy
  • Co-Leader, Tumor Immunology & Immunotherapy Program
  • Rustum Family Professor for Molecular Therapeutics and Translational Research
  • Professor of Oncology

Background

Education and Training:

  • 1991 - MD, Warsaw Medical Academy (AMW), Poland
  • 1998 - PhD, Immunology, University of Amsterdam (UvA), The Netherlands

Residency:

  • 1994 - Residency, Medicine, Ctr. Clin. Hosp. Milit. Sch. Med, Warsaw, Poland

Fellowship:

  • 2000 - Fellowship, Immunology, University of Amsterdam (UvA), The Netherlands
  • 1992 - Research Fellowship, Immunology, University of Amsterdam (UvA) The Netherlands

Professional Memberships:

  • 2015 - American Society of Clinical Investigation
  • 2011 - American Association for Cancer Research
  • 2009 - Society for Clinical and Translational Science
  • 2008 - Society for Immunotherapy of Cancer
  • 2004 - Society for Natural Immunity
  • 2001 - American Association of Immunologists

Publications

Full Publications list on PubMed
  • Kalinski P., C. M. U. Hilkens, E. A. Wierenga, and M. L. Kapsenberg. (1999). T-cell priming by dendritic cells: the concept of a third signal. Immunol. Today 20: 561-567. PMID: 10562707
  • Mailliard, R. B., A. Wankowicz-Kalinska, Q. Cai, A. Wesa, M. L. Kapsenberg, J. M. Kirkwood, W. J. Storkus, and P. Kalinski (2004). Alpha-type-1 Dendritic Cells (αDC1): A Novel Immunization Tool with Optimized CTL-inducing Activity. Canc. Res. 64: 5934-5937.* PMID: 15342370
  • Okada, H., P. Kalinski, R. Ueda, A. Hoji, G. Kohanbash, T. E. Donegan, A. H. Mintz, J. A. Engh, D. L. Bartlett, C. K. Brown, H. Zeh, M. P. Holtzman, T. A. Reinhart, T. L. Whiteside, L. H. Butterfield, R. L. Hamilton, D. M. Potter, I. F. Pollack, A. M. Salazar, and F. S. Lieberman. (2010) Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With {alpha}-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. J Clin Oncol. 20;29(3):330-6. (2011) PMID: 21149657
  • Ravikumar Muthuswamy, Erik Berk, Beth Fallert Junecko, Herbert J. Zeh, Amer H. Zureikat, Daniel Normolle, The Minh Luong, Todd A. Reinhart, David. L. Bartlett, and Pawel Kalinski. (2012). NF-kB hyper-activation in tumor tissues allows tumor-selective reprogramming of chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 72(15):3735-43. PMID: 22593190
  • Nataša Obermajer, Jeffrey L. Wong, Robert P. Edwards, Kong Chen, Melanie Scott, Shabaana Khader, Jay K. Kolls, Kunle Odunsi, Timothy R. Billiar, and Pawel Kalinski. (2013). Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J. Exp. Med. 210 : 1433-1445, PMID: 23797095
  • Muthuswamy, Ravikumar; Nana Okada; Frank Jenkins; Kandace McGuire; Priscilla McAuliffe; Herbert Zeh; David Bartlett; Callen Wallace; Simon Watkins; Jill Henning; Dana Bovbjerg; Pawel Kalinski. (2017). Epinephrine Promotes COX-2-dependent Immune Suppression in Myeloid Cells and Cancer Tissues. Brain Behavior and Immunity, 62:78-86. PMID: 28212885

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment